Health
Bristol Myers Squibb’s Anti-MTBR-Tau-Targeting Antibody, BMS-986446, Granted Fast Track Designation by U.S. FDA for the Treatment of Alzheimer’s Disease
PRINCETON, N.J., October 01, 2025--BMS's Anti-MTBR-Tau-Targeting Antibody, BMS-986446, Granted Fast Track Designation by U.S. FDA for the Treatment of Alzheimer’s Disease
About this update from Bristol-myers Squibb Company
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1497,"height":206,"url":"https://media.zenfs.com/en/business-wire.com/001e8383b2984340af41c5bc422141c4"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/WkyUT3r0drZ3MZYn6F7Xyg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTEzMjtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/001e8383b2984340af41c5bc422141c4","width":960,"height":132},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/Czyt3fCboEu1zXadBwG.Yw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD0zMzA7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/001e8383b2984340af41c5bc422141c4","width":1200,"height":165}},"lazy":false},{"type":"text","content":"Anti-microtubule binding region-tau antibody being investigated as a potential disease-modifying therapy to slow or delay progression of disease","length":144,"tagName":"p","attribs":{}},{"type":"text","content":"Fast Track Designation recognizes the potential of anti-MTBR tau to be an important treatment option for patients with Alzheimer’s disease","length":138,"tagName":"p","attribs":{}},{"type":"text","content":"PRINCETON, N.J., October 01, 2025--(BUSINESS WIRE)--Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to BMS-986446, a potential best-in-class anti-microtubule binding region-tau (anti-MTBR-tau) antibody currently in Phase 2 development for the treatment of early Alzheimer’s disease. Fast Track Designation is intended to facilitate the development and expedite the review of investigational drugs that treat serious conditions and fill an unmet medical need.","length":543,"tagName":"p"},{"type":"text","content":"Alzheimer’s disease — the most common type of dementia in adults — is a progressive, multifaceted and devastating neurodegenerative disease in which significant changes occur in the brain that cause neurons to die over time. These changes include the accumulation and spread of pathological tau, an abnormal form of the tau protein. Pathological tau protein fragments containing the microtubule binding region (MTBR) appear to have a key role in the underlying pathology of Alzheimer’s disease. By neutralizing the spread and promoting the clearance of pathological tau, BMS-986446 aims to modify the underl...